Department of Surgery, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing 100142, China.
World J Surg Oncol. 2011 Sep 26;9:110. doi: 10.1186/1477-7819-9-110.
This study assessed the postoperative morbidity and mortality occurring in the first 30 days after radical gastrectomy by comparing gastric cancer patients who did or did not receive the FOLFOX7 regimen of neoadjuvant chemotherapy.
We completed a retrospective analysis of 377 patients after their radical gastrectomies were performed in our department between 2005 and 2009. Two groups of patients were studied: the SURG group received surgical treatment immediately after diagnosis; the NACT underwent surgery after 2-6 cycles of neoadjuvant chemotherapy.
There were 267 patients in the SURG group and 110 patients in the NACT group. The NACT group had more proximal tumours (P = 0.000), more total/proximal gastrectomies (P = 0.000) and longer operative time (P = 0.005) than the SURG group. Morbidity was 10.0% in the NACT patients and 17.2% in the SURG patients (P = 0.075). There were two cases of postoperative death, both in the SURG group (P = 1.000). No changes in complications or mortality rate were observed between the SURG and NACT groups.
The FOLFOX7 neoadjuvant chemotherapy is not associated with increased postoperative morbidity, indicating that the FOLFOX7 neoadjuvant chemotherapy is a safe choice for the treatment of local advanced gastric cancer.
本研究通过比较接受或未接受新辅助化疗 FOLFOX7 方案的胃癌患者，评估了根治性胃切除术后 30 天内发生的术后发病率和死亡率。
我们对 2005 年至 2009 年期间在我科行根治性胃切除术的 377 例患者进行了回顾性分析。研究了两组患者：SURG 组在确诊后立即接受手术治疗；NACT 组在接受 2-6 个周期的新辅助化疗后进行手术。
SURG 组有 267 例患者，NACT 组有 110 例患者。NACT 组近端肿瘤比例更高（P = 0.000），全胃/近端胃切除术更多（P = 0.000），手术时间更长（P = 0.005）。NACT 组的发病率为 10.0%，SURG 组为 17.2%（P = 0.075）。SURG 组有 2 例术后死亡（P = 1.000）。SURG 组和 NACT 组之间的并发症或死亡率没有变化。
FOLFOX7 新辅助化疗不会增加术后发病率，表明 FOLFOX7 新辅助化疗是治疗局部晚期胃癌的安全选择。
